Literature DB >> 3011259

Vindesine and mitomycin in the treatment of advanced non-small cell lung cancer: a Southeastern Cancer Study Group Trial.

D W Luedke, S L Luedke, O Martelo, P Quesenberry, R Birch, J Schlueter, J Hake, T Logan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3011259

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

Authors:  C Gridelli; R Pepe; S Palmeri; S Iacobelli; M Gentile; V Gebbia; C Garufi; G Airoma; G Palmieri; A Russo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer.

Authors:  C Gridelli; G Airoma; P Incoronato; R Pepe; G Palazzolo; A Rossi; A R Bianco
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.

Authors:  G Giaccone; M Bagatella; M Donadio; G M Bonardi; F Testore; P Ferrati; L Ciuffreda; A Calciati
Journal:  Br J Cancer       Date:  1987-10       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.